PTPI - LAZR ARWR and BXRX among pre-market losers
2023-04-25 08:29:42 ET
- Baudax Bio ( BXRX ) -74% announces positive top-line final results from phase 2 randomized clinical trial of BX1000.
- Morphic Holding ( MORF ) -34% as lead asset meets key goal in mid-stage trial.
- CXApp ( CXAI ) -32% .
- ZeroFox Holdings ( ZFOX ) -22% .
- Arrowhead Pharmaceuticals ( ARWR ) -17% achieves high levels of target gene knockdown and long duration of effect.
- Petros Pharmaceuticals ( PTPI ) -12% .
- Trio Petroleum ( TPET ) -11% .
- POET Technologies ( POET ) -9% introduces “POET Starlight” for the artificial intelligence market and receives advanced purchase order from celestial AI.
- Lyra Therapeutics ( LYRA ) -8% announces restart of pivotal phase 3 ENLIGHTEN II clinical trial of LYR-210 in chronic rhinosinusitis.
- Bullfrog AI Holdings ( BFRG ) -8%.
- Luminar Technologies ( LAZR ) -7% .
- SMX (Security Matters) ( SMX ) -5% on preparing irish investigatory capabilities against possible illegal shorts and spoofing.
- Tenet Healthcare Corporation ( THC ) - 5% . after Q4 earnings release .
For further details see:
LAZR, ARWR and BXRX among pre-market losers